Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
Medtronic
Chubb
QuintilesIMS
UBS
Federal Trade Commission
Chinese Patent Office
Harvard Business School
Merck
Farmers Insurance

Generated: January 18, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 076485

« Back to Dashboard

NDA 076485 describes MYORISAN, which is a drug marketed by Douglas Pharms and is included in one NDA. It is available from two suppliers. Additional details are available on the MYORISAN profile page.

The generic ingredient in MYORISAN is isotretinoin. There are eleven drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the isotretinoin profile page.
Summary for 076485
Tradename:MYORISAN
Applicant:Douglas Pharms
Ingredient:isotretinoin
Patents:0
Therapeutic Class:Dermatological Agents
Formulation / Manufacturing:see details
Pharmacology for NDA: 076485
Ingredient-typeRetinoids
Medical Subject Heading (MeSH) Categories for 076485
Suppliers and Packaging for NDA: 076485
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
MYORISAN isotretinoin CAPSULE;ORAL 076485 ANDA Physicians Total Care, Inc. 54868-6366 54868-6366-0 3 BLISTER PACK in 1 CARTON (54868-6366-0) > 10 CAPSULE, LIQUID FILLED in 1 BLISTER PACK
MYORISAN isotretinoin CAPSULE;ORAL 076485 ANDA Physicians Total Care, Inc. 54868-6378 54868-6378-0 3 BLISTER PACK in 1 CARTON (54868-6378-0) > 10 CAPSULE, LIQUID FILLED in 1 BLISTER PACK

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength10MG
Approval Date:Jan 19, 2012TE:ABRLD:No

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength20MG
Approval Date:Jan 19, 2012TE:ABRLD:No

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength40MG
Approval Date:Jan 19, 2012TE:ABRLD:No

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Argus Health
Johnson and Johnson
Covington
Queensland Health
Boehringer Ingelheim
Farmers Insurance
Harvard Business School
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot